论文部分内容阅读
尿毒症患者经血液净化治疗,临床表现有改善,但却不能满意地纠正肾性贫血。一般内科治疗贫血的方法效果都不明显,男性激素治疗和小量输血虽能暂时缓解症状,但有副作用,故肾性贫血的治疗仍是国内当前治疗尿毒症中的一个难题。自1985年基因重组人红细胞生成素(recombinant human erythropoietin,rHuEpo)问世以来,美、英、日本、加拿大和西欧诸国都先后将rHuEpo试用于临床,取得了突破性进展。1991年初我国开始试用,目前尚无经验总结。本文综述近年来国外应用rHuEpo治疗慢性肾功能衰竭患者贫血的经验。
Uremic patients treated with blood purification, clinical manifestations improved, but not satisfactorily correct renal anemia. General medical treatment of anemia effect is not obvious, although the male hormone therapy and small amount of blood transfusion can temporarily relieve the symptoms, but there are side effects, so the treatment of renal anemia is still the current domestic treatment of uremia in a problem. Since the advent of recombinant human erythropoietin (rHuEpo) in 1985, rHuEpo has been used clinically in the United States, Britain, Japan, Canada, and Western Europe and achieved breakthroughs. At the beginning of 1991, our country began trial, there is no experience to conclude. This review summarizes the experience of rHuEpo in the treatment of anemia in patients with chronic renal failure in recent years.